Turkish Journal of Medical Sciences
Volume 38

Number 5

Article 13

1-1-2008

Clinical and Rhinoscintigraphic Evaluation of Oral Macrolides in
the Management of Sinonasal Polyposis
EMİNE AYDIN
HÜLYA ORTAPAMUK
HAKAN KORKMAZ
ENGİN DURSUN
ADİL ERYILMAZ

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
AYDIN, EMİNE; ORTAPAMUK, HÜLYA; KORKMAZ, HAKAN; DURSUN, ENGİN; ERYILMAZ, ADİL; SAYLAM,
GÜLESER; and DAĞLI, MUHARREM (2008) "Clinical and Rhinoscintigraphic Evaluation of Oral Macrolides
in the Management of Sinonasal Polyposis," Turkish Journal of Medical Sciences: Vol. 38: No. 5, Article
13. Available at: https://journals.tubitak.gov.tr/medical/vol38/iss5/13

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Clinical and Rhinoscintigraphic Evaluation of Oral Macrolides in the Management
of Sinonasal Polyposis
Authors
EMİNE AYDIN, HÜLYA ORTAPAMUK, HAKAN KORKMAZ, ENGİN DURSUN, ADİL ERYILMAZ, GÜLESER
SAYLAM, and MUHARREM DAĞLI

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol38/iss5/13

ORIGINAL ARTICLE

Emine AYDIN1
Hülya ORTAPAMUK2
Hakan KORKMAZ1
Engin DURSUN1
Adil ERYILMAZ1
Güleser SAYLAM1
Muharrem DAĞLI1

1

2

Turk J Med Sci
2008; 38 (5): 465-470
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr

Clinical and Rhinoscintigraphic Evaluation of Oral
Macrolides in the Management of Sinonasal Polyposis
Aim: To document the efficacy of low-dose long-term oral macrolide treatment in the management of
sinonasal polyposis. The study was designed prospectively in a group of patients with sinonasal polyposis and
negative history of surgery.
Materials and Methods: Ten patients were administered roxithromycin (RXM) 150 mg/day single oral dose
for eight weeks. All patients underwent Tc-99m rhinoscintigraphic evaluation of mucociliary activity and
endoscopic evaluation before and after the treatments. Response to treatment, in terms of rhinoscintigraphic
and endoscopic improvement, was assessed.
Results: Of the 10 patients, 7 were male and 3 female, with an average age of 46 years (27-74). Following
treatment, mucociliary transport time was significantly reduced (P < 0.05) and the polyps were clinically
shrunk (P < 0.05).
Conclusions: It was determined that low-dose long-term oral macrolide treatment was effective in the
management of sinonasal polyposis. Macrolides can be considered, as an alternative to or in conjunction with
steroids, in the management of sinonasal polyposis.
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Sinonazal Polipozis Tedavisinde Oral Makrolidlerin Yerinin Klinik ve
Rinosintigrafik Olarak Değerlendirilmesi
Amaç: Düşük doz uzun süreli oral makrolid tedavisinin sinonazal polipoziste etkinliğini belirlemek. Çalışma,
sinonazal polipozisli ve cerrahi hikayesi olmayan bir grup hastada prospektif olarak planmıştır.
Yöntem ve Gereç: On hastaya sekiz hafta boyunca günlük 150 mg roksitromisin verilmiştir. Tüm hastalara
mukosiliar aktivitenin Tc-99m rinosintigrafik değerlendirilmesi ve tedavi öncesi ve sonrası endoskopik
değerlendirme yapıldı. Tedaviye yanıt, rinosintigrafik ve endoskopik iyileşme ile değerlendirildi.
Bulgular: On hastanın 7’si erkek ve 3’ü bayandı. Ortalama yaş 46 (27-74) idi. Tedaviyi takiben mukosilier
transport zamanı anlamlı derecede düşmüş (P < 0.05) ve polipler klinik olarak küçülmüştür (P < 0.05).
Sonuç: Düşük doz uzun süreli oral makrolid tedavisi sinonazal polipozisin tedavisinde etkilidir. Makrolidlerin,
sinonazal polipozis tedavisinde bir alternatif olarak veya steroidlerle bir arada kullanımı düşünülebilir.
Anahtar Sözcükler: Sinonazal polip, nazal polip, nazal polipozis, makrolid, rinosintigrafi
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Sinonasal polyposis (SNP) represents an important clinical problem, with several local
and/or systemic manifestations, and its prevalence ranges from 0.2 to 4.3% in the
general population. SNP is considered to result from a chronic inflammation, and is
characterized by edematous masses of mucosa prolapsing into the nose. Multiple factors,
local and/or systemic, can play a role in the etiology. It can sometimes be associated with
systemic diseases such as asthma, cystic fibrosis, primary ciliary dyskinesia, aspirin
sensitivity, and allergy. Major symptoms are nasal obstruction, increased secretions, loss
of smell, and headache, which may result in significantly reduced quality of life (1-5).
Management includes medical treatment and/or surgery, and can be quite challenging
in some patients. Disease extension and systemic status are important in making the
treatment decision. Medical treatment with various combinations is considered in both
pre- and postoperative periods. Topical and/or systemic steroids are usually preferred.
Endoscopic surgery is complementary but recurrences are frequent in the long-term.
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Nasal endoscopic examination was used for the clinical
assessment of polyps and rhinoscintigraphy for evaluating
the mucociliary activity. Both studies were performed
before and after the treatment in all patients.
Improvement in SNP-related symptoms was also
evaluated in each patient.

Therefore, even the best surgery should be followed by
postoperative medical treatment (1-7).
In the search for alternative medical treatments, oral
macrolides have been increasingly reported to reduce
nasal polyps due to their anti-inflammatory effects (8,9).
The aim of this study was to document the therapeutic
effects of oral macrolides in SNP. We utilized
rhinoscintigraphy to assess the mucociliary activity and
endoscopic examination to evaluate clinical response.

Nasal examination: Diagnostic nasal endoscopy was
done with topical anesthesia in sitting position with a rigid
endoscope (4 mm, Storz-wide angle 0°). No decongestion
or local anesthesia was used. The mass of the polyps in
each nostril was assessed and the patients were staged
according to the system of Lund and Mackay (10)
(Table 1).

Materials and Methods
Patients
The study involved 10 adult patients with SNP. The
patients who had systemic and/or infectious diseases,
history of nasal or systemic steroid application in the last 3
months, or history of sinonasal operations were excluded.

Rhinoscintigraphy: A gamma camera (Elscint SPX-6,
Haifa, Israel) with a low-energy high-resolution
collimator was used. Patients were positioned sitting in
front of the gamma camera, with the involved nostril
touching the collimator. Tc-99m MAA (macroaggregated
albumin) (1.85 MBq; 50 μCi) was insufflated into the
nostril while the patients held their breath. A spray
applicator (nominal ejection volume, 50 μl) with a 2%
aqueous solution of propylene glycol was used. The
acquisition was immediately started, storing 30-second

The study was designed prospectively in a single
institution and was approved by the ethical committee.
The patients received 150 mg/day oral single dose of
roxithromycin (RXM) for 8 weeks. Clinical and
rhinoscintigraphic improvement profiles were utilized to
evaluate the success rates.

Table 1. Special features of all patients before and after treatment.
Sex

Age

Pre-treatment
Stage

Post-treatment
Stage

Pre-treatment
MTT (minute)

Post-treatment
MTT (minute)

M

27

2

1

56.50

30.10

F

30

2

2

25.70

20.50

M

56

2

2

47.50

18.87

M

29

3

2

15.10

14.98

M

74

3

2

39.20

19.90

F

36

2

2

46.00

32.30

F

37

2

2

134.0

11.40

M

65

2

2

18.50

09.97

M

64

2

2

21.70

12.60

M

42

2

1

60.10

36.50

M: male; F: female; n: number of patients; MTT: mucociliary transport time.
The stages according to nasal endoscopic findings were as follows:
Stage-0: No polyp.
Stage-1: Polyps are limited to the middle meatus.
Stage-2: Polyps beyond the middle meatus but not completely obstructing the nasal cavity.
Stage-3: Polyps completely obstructing the nasal cavity.
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frames for a total of 15 minutes per study. Two
radioactive markers were placed on the mastoid and
external acoustic meatus and then recorded. If no activity
appeared in the pharynx, late static images were obtained
1 hour after radiopharmaceutical insufflation.
Regions of interest were drawn in the nasal cavity and
pharynx. With the aid of radioactive markers, the
separation between the palate and the pharynx was
identified; here the radioactivity appeared as a downward
and backward inclined area at the “end” of the scintigraphic
pattern. Time-activity curves were obtained from each
region of interest. The exact time when the radioactivity
entered the pharynx was individualized using external
markers, sequential images, and time-activity curves. The
length of the radioactivity path from the hyperactive area
corresponding to the insufflated radiopharmaceutical to the
end of the nasal activity was displayed directly by the
computer, transforming the number of pixels into
millimeters. Mucociliary transport time (MTT) was then
calculated by dividing length by exact time.
Assessment
Clinical and rhinoscintigraphic outcomes were used in
order to assess treatment results.
Clinical assessment: A nasal endoscopy-based
staging system and a questionnaire on patient
improvement status were used. The questionnaires were
completed by the patients under the observation of a
resident, and nasal endoscopies were performed by the
authors (HK, ED, AE) at each visit after the treatment.
Final data at the 8th week visit was used as the end point
of symptom profile and stage. Six SNP-related symptoms
were evaluated.
Rhinoscintigraphic assessment: MTT was used for
evaluating mucociliary function. The examinations were
done before and after the treatment.

Results
Of the 10 patients, 7 were male and 3 female, with an
average age of 46 years (27-74). Patients were staged
endoscopically; 8 were in stage-2 and 2 were in stage-3
before the treatment. Eight patients were in stage-2 and
2 were in stage-1 after the treatment (Table 1). Four
patients were downstaged, and the average of the stages
was improved from 2.20±0.42 to 1.80±0.42 after the
treatment (P < 0.05) (Table 2).
The average MTT was improved from 46.43±34.66
to 20.71±9.28 after the treatment (P < 0.05) (Table 3).
Nasal stuffiness was the most common complaint. The
improvement scores for the most frequent symptoms
were as follows: nasal stuffiness improved in 22.2%,
nasal drainage in 71.4%, and postnasal drainage in 25%
of patients (Table 4).

Discussion
SNP is the most incapacitating benign disease of the
nose, and its treatment is a subject of debate among
clinicians and researchers. It is a multifactorial disease,
and the current information about the cause and
pathogenesis is inadequate for its cure. Several
hypotheses have been put forward in the etiology,
including systemic, local and genetic factors. Aspirin
intolerance, epithelial cell defects/gene deletions, cystic
fibrosis and ciliary dyskinesia, inhalant or food allergies,
and altered Na+ absorption are all considered to be

Table 2. The stages before and after treatment (n: number of patients).
Pre-treatment

Post-treatment

Stage
n

%

n

0

0

0

0

0

1

0

0

2

20

2

8

80

8

80

3

2

20

0

0

Statistical Analysis
Data were analyzed with the use of nonparametric
statistics. All data were reported as medians with the
interquartile range unless otherwise stated. Paired
comparisons within a group were analyzed with the
Wilcoxon signed rank test. Group comparisons were
analyzed with the Mann-Whitney U test. A P value of
<0.05 (2-tailed) was considered significant. Statistical
Package for the Social Sciences (SPSS) 11.0 for Windows
software was used.

October 2008

%

Median
(min-max)

2 (2-3)

2 (1-2)

Mean
(mean±SD)

2.20±0.42

1.80±0.42
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Table 3. Mucociliary transport time before and after treatment.
Mucociliary Transport Time
Mean ± SD

Median (min-max)

Pre-treatment

Post-treatment

Pre-treatment

Post-treatment

42.60 ± 34.66

19.38 ± 9.28

42.60 (15.10-134)

19.38 (9.97-36.50)

Table 4. Pre-treatment and post-treatment symptoms and their improvement rates (n:
frequency of patients’ symptoms).
Pre-treatment

Post-treatment

Improvement

n

n

n

%

Symptoms
%

Nasal drainage

7

70

2

20

5

71.4

Postnasal drainage

4

40

3

30

1

25

Nasal stuffiness

9

90

7

70

2

22.2

Headache

9

90

8

80

1

11.1

Facial pain

5

50

5

50

0

0

Smell disorders

5

50

5

50

0

0

involved. Local mucosal and environmental factors are
also important, resulting in alteration of aerodynamics
with trapping of pollutants and epithelial disruptions
(2,7,11-13). The other possible mechanism involves
bacterial colonization of the nasal cavity, causing
synthesis and release of enterotoxins that act as
superantigens to stimulate the local immune system (14).
In fact, the presence of inflammatory mediators is a
prominent and common factor in SNP, indicating that
chronic persistent inflammation is undoubtedly a major
factor irrespective of the etiology (2,4,7,11-13).
Although the origin of polyps is not well understood,
nasal polyps are well described in terms of cell types and
cytokine content. Accumulation of eosinophils,
neutrophils, plasma and mast cells, macrophages, and
lymphocytes is a frequent finding, and there is much
evidence on the activity and pathogenic role of these cells
(2,13). A series of cytokines such as interleukin (IL)-1 ,
IL-3, IL-4, IL-5, IL-6, and IL-8, transforming growth
factor-beta (TGF-beta), granulocyte-macrophage colonystimulating factor (GM-CSF), chemokines such as eotaxin,
RANTES and adhesion molecules (E-Selectin and PSelectin, VCAM-1) are considered to be involved in the

468

%

formation of polyps (2,8,13). The arachidonic acid
pathway may also play a role in the initiation of polyposis,
as well as the elevated 5-lipooxygenase activity (15).
Most authors agree that SNP management should be
primarily based on medical treatment followed by
complementary endoscopic sinus surgery in persistent
cases (1-7). The aim of the medical treatment is to reduce
polyp size, relieve symptoms, facilitate operative
procedure and prevent recurrences. Systemic and/or
intranasal (topical) steroids are the main medications
used. Topical steroids can be used long-term either alone
in mild cases or combined with systemic steroids and/or
surgery in more severe cases (1,2,4,6). The efficacy of
systemic steroids is well-known, but their usage is limited
because of their potential adverse effects even in a
healthy population. They are contraindicated and
hazardous in a wide spectrum of diseases such as
hypertension, diabetes mellitus, obesity, osteoporosis and
glaucoma. Systemic effects of topical steroids are very
rare, and use of these drugs does not cause dystrophy or
atrophy of the nasal mucosa, but they are associated with
some local side effects such as burning sensation,
epistaxis, and oral candidiasis. Because of their wide
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safety margins, these drugs have been used more than
systemic steroids in clinical practice (6,16).
Macrolides have been used for decades as an important
chemotherapeutic agent in the treatment of infectious
diseases (8,9). The intracellular accumulation of
macrolides altering the host cell functions has recently
triggered a new interest in their therapeutic potential in
clinical settings other than infections (17). A growing body
of experimental and clinical evidence indicates that
macrolide antibiotics possess distinct salutary properties
that promote and sustain the reparative process in the
chronically inflamed upper and lower respiratory tract
(17,18). Potential effects of macrolides are to decrease
the virulence of bacteria and suppress the production of
bacterial toxins and biofilm formation. On the host site,
they inhibit the activation of pro-inflammatory genes,
increase apoptosis and degranulation of neutrophils,
improve mucociliary transport and reduce goblet cell
secretion (8). Many investigators have reported that antiinflammatory effects of macrolides compete with their
anti-bacterial effects (19). These distinct effects are
expressed at lower doses, usually after a relatively
prolonged period (weeks) of treatment, and in the absence
of identifiable, viable pathogens. Long-term low-dose
administration of macrolide antibiotics is not associated
with increased incidence of adverse events, relevant
bacterial resistance, or immunosuppression (8,18).
Erythromycin (EM) is the original macrolide molecule,
and clarithromycin (CAM), RXM and azithromycin (AZM)
are new semi-synthetic derivatives of EM. In vitro studies
also support the view that there are no major differences
in anti-inflammatory efficacy. The higher incidence of
gastrointestinal side effects of EM suggests that newer
macrolides, with better absorption and fewer side effects,
can be preferred (8). The anti-inflammatory effects of
RXM, CAM and AZM were compared in an experimental
rat study. When rats were given a prophylactic dose of
RXM, it suppressed the edema produced by injecting
carrageenin into the paw with effects almost equal to
those seen with the nonsteroidal anti-inflammatory drug
nimesulide. However, AZM and CAM showed only slight
anti-inflammatory effects (20).
These evidences suggest that macrolides can be
effective in treating chronic rhinosinusitis (CRS) and SNP.
In a clinical study, EM was found to improve MTT and
decrease secretions in CRS and SNP (8). Our findings
were also parallel to the results of this study.
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In the human nose, the mucous flow is predominantly
posterior towards the nasopharynx, streaming above and
below the tubal opening. Nasal mucociliary transport is
disturbed in a variety of conditions that affect the activity
of the cilia. If there is a defect associated with pooling of
the mucus or with squamous metaplasia, normal
mucociliary transport will be lost at this site. SNP is
edematous swelling of the nasal mucosa. The ciliated
surface can undergo squamous metaplasia. When the
mucociliary blanket is preserved, the mucous moves in
the normal fashion, but with pedunculated swelling of the
mucosa, the direction of the mucous flow may be
changed. Patients with SNP have disturbed mucociliary
function (21). MTT is a highly reproducible parameter
and can be used to compare the therapy results (22).
Various well-established methods to study the ciliary
activity of nasal mucosa are available. Direct methods
such as stroboscopy, roentgenography, and
photoelectron techniques are performed to assess the
ciliary activity and the frequency of ciliary beat, but they
are expensive and unsuitable for routine studies. Indirect
methods use soluble, insoluble, or radioactive substances
to assess nose-to-pharynx transport times. Saccharine
and vegetal-carbon powder testing is the easiest and most
inexpensive technique to evaluate nasal ciliary function
(22). However, gamma scintigraphy (rhinoscintigraphy)
provides the most physiological information about the
deposition, dispersion and clearance of particles in the
nose. It follows the movement of many particles once
they have been deposited in the nasal cavity, rather than
the movement of individual particles or the passage of a
substance in solution such as saccharin (21). Thus, it
appears to accomplish some significant goals in the
research on the ciliary system of the nasal mucosa.
However, the equipment is expensive, the patient has to
remain in a room suitable for radioactive materials and
the subject is exposed to the radiation. Various
radiopharmaceuticals (colloidal solutions, resin particles,
51
and albumin microspheres) labeled with Cr or I-131
have been proposed for rhinoscintigraphy. Tc-99m MAA
is preferred by most authors because it is cost-effective
and has more suitable physical characteristics and does
not allow radiation burden. MTT has been calculated as a
mean 5.3 mm/min (range 3.3-8.2 mm/min) by
rhinoscintigraphy (22).
In our study, we used Tc-99m MAA to compare the
therapeutic effects of RXM objectively. The test was
469
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successfully applied in all patients without any
complication, and we were able to obtain satisfactory
data. We determined that MTT decreased from 42.60 ±
34.66 to 19.38 ± 9.28, which revealed a significant
improvement. We also used endoscopic evaluation to
monitor the clinical response of the disease. We observed
significant clinical improvement in accordance with the
findings of rhinoscintigraphy. After the treatment, the
stages were downgraded from 2.20 ± 0.42 to 1.80 ±
0.42.
Our findings were parallel to those in the literature,
which revealed the efficacy of RXM in the medical
treatment of SNP. The drawback of this study is the
limited number of patients. Nevertheless, it is still possible
to recommend that macrolides be considered in the

Turk J Med Sci

treatment of SNP. Further studies with a higher number of
patients should be designed to study preoperative and
postoperative treatment alternatives. With the information
available, we believe that macrolides are good treatment
alternatives in the management of SNP, either in
conjunction with steroids or as a replacement.
In conclusion, RXM was used in this study in the
medical treatment of SNP. After RXM treatment, polyp
size decreased, symptoms improved and mucociliary
transport increased (MTT decreased). It was seen that a
low-dose macrolide treatment was effective in the
treatment of SNP. It is believed that macrolides can be an
alternative to nasal and systemic steroids in the
management of SNP, especially in patients in whom
steroid use is contraindicated.
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